RTP Mobile Logo
Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Gastrointestinal Cancers
Released September 2018

Featuring key slides from the most important recent gastrointestinal cancer presentations and publications and video interviews with Dr Tanios Bekaii-Saab and Dr Eileen M O’Reilly. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals involved in the treatment of gastrointestinal (GI) cancers.

    Because of the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Interestingly, however, although individually less frequently encountered, the collection of other, “non-CRC” gastrointestinal (GI) cancers accounts for more cancer-related deaths per annum than those attributed to tumors of the colon and rectum combined. Therefore, educational opportunities relevant to the clinical management of both CRC and the most prevalent non-CRC GI tumors — including gastric, pancreatic and hepatocellular cancer — are essential to the general oncologist’s delivery of comprehensive cancer care.

    As it is simply not possible for one general oncologist to review and make sense of the massive volume of information emerging across one disease, let alone all of the tumor types he or she is responsible for treating, the overarching objective of RTP’s Year in Review On Demand video program is to provide an efficient and timely overview of key presentations and publications emerging over the course of the past 12 months and provide perspectives on how this information can and should be applied to patient care.

    To bridge the gap between research and patient care, the YiR On Demand video program features one-on-one discussions with leading medical oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this CME activity assists medical oncologists, hematology-oncology fellows and other allied healthcare professionals with the formulation of evidence-based and current therapeutic strategies.


    • Compare and contrast the clinical applicability of emerging research findings, as published in peer-reviewed journals and/or presented at major oncology conferences, specific to GI cancers, including colorectal, pancreatic and gastric cancer and hepatocellular carcinoma.
    • Develop a long-term care plan for patients diagnosed with metastatic CRC, considering biomarker profile, tumor location, prior systemic therapy, symptomatology, performance status (PS) and personal goals of treatment.
    • Consider HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to tailor the selection and sequence of systemic therapy for locally advanced or metastatic gastric or gastroesophageal cancer.
    • Use age, PS and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic adenocarcinoma.
    • Discuss with patients the benefits and risks of available and emerging systemic interventions for locally advanced or metastatic hepatocellular carcinoma.
    • Evaluate the rationale for and clinical data with commercially available and investigational immune checkpoint inhibitors in the treatment of GI cancers.
    • Appropriately select and counsel patients with GI cancers about participation in ongoing clinical trials evaluating novel therapeutic agents and strategies.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of slide and video components.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Tanios Bekaii-Saab, MD
    Professor, Mayo Clinic College of Medicine and Science
    Co-Leader, GI Cancer Program, Mayo Clinic Cancer Center
    Senior Assistant Consultant
    Mayo Clinic, Arizona
    Scottsdale, Arizona

    Consulting Agreements: Amgen Inc, ARMO BioSciences, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Exelixis Inc, Genentech, Ipsen Biopharmaceuticals Inc, Merck, Roche Laboratories Inc, SillaJen; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Lilly.

    Eileen M O'Reilly, MD
    Associate Director, Clinical Research
    David M Rubenstein Center for Pancreatic Cancer Research
    Attending Physician, Member
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Medical College of Cornell University
    New York, New York

    Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Antengene, Aptus, ASLAN Pharmaceuticals, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Bristol-Myers Squibb Company, CARsgen, CASI Pharmaceuticals, Celgene Corporation, CytomX Therapeutics, Daiichi Sankyo Inc, Debiopharm Group, Delcath Systems Inc, Eisai Inc, Exelixis Inc, Genentech, Gilead Sciences Inc, Halozyme Inc, Incyte Corporation, Inovio Pharmaceuticals Inc, Lilly, Merck, Onxeo, PCI Biotech, Roche Laboratories Inc, Sanofi Genzyme, Servier, Silenseed Ltd, SillaJen, Sirtex Medical Ltd, Vicus Therapeutics, Yakult Pharmaceutical Industry Co Ltd; Contracted Research: Agios Pharmaceuticals Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, CASI Pharmaceuticals, Celgene Corporation, Exelixis Inc, Genentech, Incyte Corporation, MabVax Therapeutics, MedImmune Inc, Momenta Pharmaceuticals Inc, Novartis, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Ipsen Biopharmaceuticals Inc and Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: September 2018
    Expiration date: September 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Colorectal Cancer (CRC)
(Dr Bekaii-Saab)

Gastric Cancer
(Dr Bekaii-Saab)

Pancreatic Cancer
(Dr O’Reilly)

Hepatocellular Carcinoma (HCC)
(Dr O’Reilly)

Select Publications

Slide Presentation